IL10 and inflammatory bowel disease: We hypothesized that deletion of pro-inflammatory Ogr1 balances out the absence of anti-inflammatory Il-10 and Tdag8, and consequently OGR1 inhibition represents a potential therapeutic option in IBD, particularly for patients carrying mutations in the CD susceptibility gene TDAG8.